Finance committee  Yes, that's a very fair statement. I think a lot of it is about defining the issue that needs to be resolved and then working together to solve the how.

Finance committee  The data protection provisions in the USMCA are looking at an extension of the protection for biologic medicine, a specific class of medicines, for an additional two years. It's all fairly new to all of us. We are currently in the process of going through the text and trying to g

Finance committee  Thank you, Ms. Alleslev. I'll try to respond to this efficiently. The government is trying to propose new criteria or new factors in terms of setting price. If we think about the role of the federal government, it is a price regulator. Its mandate is to ensure that prices in Can

Finance committee  Thank you, Mr. Sobara. The terminology is “Don't throw out the baby with the bathwater.” To your point, frankly, the majority of Canadians in fact have some form of coverage, whether it be public or private. There's been a recent Conference Board of Canada analysis that's been

Finance committee  Very good. Thank you.

Finance committee  Thank you for the question, Mr. Sorbara. In terms of the patented medicines regulations, what we are really looking for is an opportunity to ensure that in health and innovation policies a whole-of-government approach is taken towards addressing the affordability challenges in t

Finance committee  Mr. Chairman, vice-chair and committee members, thank you for giving me this opportunity to address you on behalf of Merck Canada, one of the major innovative biopharmaceutical companies in Canada. Merck Canada and the pharmaceutical industry are currently in the midst of an e